{
  "htmlTitle": "Invega Sustenna® dosing conversion guides",
  "modal": {
    "title": "Important Safety Information",
    "p_1a": "(paliperidone palmitate) is indicated for the treatment of schizophrenia in adult patients. In controlled clinical trials, ",
    "p_1b": "was found to improve the symptoms of schizophrenia, including positive and negative symptoms.",
    "p_2a": "is indicated for the maintenance treatment of schizoaffective disorder in adult patients.",
    "p_3a": ", a 3-month injection, is indicated for the treatment of schizophrenia in adult patients.",
    "p_3b": "is to be used only after",
    "p_3c": "(1-month paliperidone palmitate prolonged-release injectable suspension) has been established as adequate treatment for at least four months. In order to establish a consistent maintenance dose, it is recommended that the last two doses of",
    "p_3d": "be the same dosage strength before starting",
    "pm_a": "Please consult the Product Monograph at ",
    "pm_url": "https://www.janssen.com/canada/products",
    "pm_b": " for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use.",
    "continue": "Continue to website"
  },
  "safety_info": "Safety Information",
  "switching_from": "Switching from ",
  "adapted_from": "Adapted from the ",
  "product_m": "Product Monograph",
  "nav": {
    "home": "Home",
    "alt_sustenna": "ONCE-MONTHLY Invega Sustenna® paliperidone palmitate PROLONGED-RELEASE INJECTABLE SUSPENSION",
    "alt_trinza": "Invega Trinza® paliperidone palmitate prolonged-release injectable suspension 175 mg, 263 mg, 350 mg, 525 mg"
  },
  "home": {
    "title": "Dosing Conversion Guides",
    "btn_1a": "Oral Antipsychotics to",
    "btn_1b": "Dosing Conversion Guide"
  },
  "guide1": {
    "h1_a": "Oral Antipsychotic to ",
    "h1_b": "Conversion Guide",
    "h2_a": "Switching to ",
    "h2_b": "from Oral Antipsychotic Medications",
    "p1_a": "For patients who have never taken oral paliperidone or oral/injectable risperidone, tolerability should be established with oral paliperidone or oral risperidone prior to initiating treatment with ",
    "p2_a": "There are no systematically collected efficacy or safety data to specifically address switching patients with schizophrenia or schizoaffective disorder from other antipsychotics to ",
    "p2_b": " or concerning concomitant administration with other antipsychotics.",
    "p3": "Very rare cases of severe hypersensitivity after injection with 1-month injectable paliperidone have been reported during post-marketing experience in patients who have previously tolerated oral paliperidone or oral risperidone. Care should be taken to avoid exposure to those that are suspected to be hypersensitive or have shown hypersensitivity reactions to any of the excipients.",
    "panelA": {
      "h3": "Other Oral Antipsychotics",
      "span": "When starting ",
      "li_1": "Gradually discontinue the previous oral antipsychotic in accordance with the appropriate prescribing information. ",
      "initiate": "Initiate ",
      "li_2": " according to the recommended initiation dosing regimen below: ",
      "day": "Day {{numOfDays}}",
      "delt": "Deltoid",
      "muscle": "Muscle",
      "alt_dose_150": "On Day 1, administer the initiation dose of 150 mg into the deltoid muscle.",
      "1_week": "1 week",
      "4_days": "4 days",
      "alt_dose_100": "1 week +/- 4 days later, on day 8 administer the second initiation dose of 100 mg into the deltoid muscle.",
      "foot_a": "See details about needle selection based on selected injection area and patient weight in the Product Monograph.",
      "foot_b": "In order to avoid a missed dose"
    },
    "panelB": {
      "h3": "Extended-Release Tablets",
      "span_a": "Following administration of the ",
      "span_b": " initiation regimen, patients previously stabilized on different doses of ",
      "span_c": " Extended-Release Tablets can attain similar paliperidone steady-state exposure during maintenance treatment with the ",
      "span_d": " doses displayed below.",
      "input_a": "If the ",
      "input_b": "once-daily",
      "input_c": " dose is:",
      "output_a": "The once-monthly ",
      "output_b": " maintenance dose needed to attain similar steady-state paliperidone exposure during maintenance treatment is:",
      "foot_a": "Note: 25 mg dose is not available in Canada",
      "foot_b": ""
    },
    "panelC": {
      "h3": "Monthly Maintenance Dosing",
      "p_a": "To avoid missed monthly doses, patients may be given their monthly maintenance injection ",
      "seven_days": "+/- 7 days",
      "p_b": " from the monthly time point.",
      "monthly": "Monthly",
      "delt_or_glut": "Deltoid or Gluteal Muscle",
      "h4_a": "Maintenance Dose for Schizophrenia",
      "alt_card_a": "Monthly maintenance doses should be administered into the deltoid or gluteal muscle. For patients with schizophrenia, the recommended monthly maintenance dose is 75 mg, with a range of 25-150 mg based on individual patient tolerability and/or efficacy. The 25 mg dose is not available in Canada.",
      "card_foot": "Recommended dose",
      "h4_b": "Maintenance Dose for",
      "sad": "Schizoaffective Disorder",
      "alt_card_b": "For patients with schizoaffective disorder, the recommended monthly maintenance dose is within the range of 50-150 mg based on tolerability and/or efficacy.",
      "foot_a": "See details about needle selection based on selected injection area and patient weight in the product monograph.",
      "foot_b": "Note: For patients with schizophrenia, the recommended monthly maintenance dose is",
      "foot_b2": "with a range of",
      "foot_b3": " based on individual patient tolerability and/or efficacy. The",
      "foot_b4": "dose is not available in Canada. For patients with schizoaffective disorder, the recommended monthly maintenance dose is within the range of",
      "foot_b5": " based on tolerability and/or efficacy.",
      "foot_b6": "Please see the Product Monograph for complete dosing information."
    }
  },
  "guide2": {
    "h1": "Dosing Conversion Guide",
    "p_a": "is to be used only after",
    "p_b": "has been established as adequate treatment for at least four months. To establish a consistent maintenance dose, it is recommended that the last two doses of",
    "p_c": "be the same dosage strength before starting",
    "text_1a": "Initiate",
    "text_1b": "in place of the next scheduled",
    "text_2a": "dose should be based on the previous",
    "text_3a": "from the next scheduled"
  },
  "footer": {
    "refs": "References: ",
    "pm": "Product Monograph. Janssen Inc. December 17, 2020. ",
    "tm": "All trademarks used under license.",
    "pp": "Privacy Policy",
    "pp_url": "https://www.janssen.com/canada/privacy",
    "terms": "Terms of Use",
    "city": "Toronto, Ontario",
    "company_url": "https://www.janssen.com/canada",
    "paab": "Reviewed by PAAB",
    "imc": "Member of Innovative Medicines Canada"
  }
}